Literature DB >> 8195626

Role of amoxicillin serum levels for successful prophylaxis of experimental endocarditis due to tolerant streptococci.

U Fluckiger1, P Francioli, J Blaser, M P Glauser, P Moreillon.   

Abstract

The importance of amoxicillin serum profiles for successful prophylaxis of experimental endocarditis in rats was assessed. Animals with catheter-induced vegetations were challenged intravenously with large inocula of Streptococcus sanguis and received one of the following amoxicillin dosages: single or multiple bolus injection of 40 mg/kg; 40 mg/kg administered as a continuous infusion over 12 h; or either 9 or 18 mg/kg administered over 12 or 24 h, respectively. The regimen producing a single transient high peak serum level failed to prevent experimental endocarditis; in contrast, a second injection 6 h after the first resulted in successful prophylaxis. Likewise, the three regimens of continuous, relatively low-dose regimens prevented infections. Thus, the most important parameter for successful prophylaxis was the duration of inhibitory concentration of the drug in the serum. The total dose of antibiotic, the peak serum levels, or the area-under-the-curve values were not predictive of successful prophylaxis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195626     DOI: 10.1093/infdis/169.6.1397

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Thrombin-induced platelet microbicidal protein susceptibility phenotype influences the outcome of oxacillin prophylaxis and therapy of experimental Staphylococcus aureus endocarditis.

Authors:  V K Dhawan; A S Bayer; M R Yeaman
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

2.  Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis.

Authors:  M S Rouse; J M Steckelberg; C M Brandt; R Patel; J M Miro; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.

Authors:  J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.

Authors:  J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

5.  Platelet microbicidal protein alone and in combination with antibiotics reduces Staphylococcus aureus adherence to platelets in vitro.

Authors:  M R Yeaman; P M Sullam; P F Dazin; A S Bayer
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

6.  Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.

Authors:  J M Entenza; Y A Que; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

7.  Efficacy of clarithromycin versus that of clindamycin for single-dose prophylaxis of experimental streptococcal endocarditis.

Authors:  D Vermot; J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats.

Authors:  U Fluckiger; P Moreillon; J Blaser; M Bickle; M P Glauser; P Francioli
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

9.  Parenteral sparfloxacin compared with ceftriaxone in treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci.

Authors:  J M Entenza; M Blatter; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

10.  Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis.

Authors:  J M Entenza; O Marchetti; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.